IP Library › Granted Patent US 11,819,795
Granted Patent B2
US 11,819,795 · App. 17/014,330 · Granted Nov 21, 2023

Trace and low concentration CO

Inventors: Mohamed Eddaoudi (Thuwal, SA); Youssef Belmabkhout (Thuwal, SA); Osama Shekhah (Thuwal, SA)
Assignee: King Abdullah University of Science and Technology
B01D53/02A61M16/22B01J20/226B01J20/28057B01J20/28083H01M8/0668B01D2253/204B01D2257/504B01D2258/0283B01D2258/06B01D2259/4533B01J2220/62Y02C20/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,819,795
App. No.
17/014,330
Granted
Nov 21, 2023
Kind
B2
Abstract

Embodiments of the present disclosure describe a device for removing CO 2 comprising a gas flow inlet, a housing including a SIFSIX-3-Cu metal-organic framework (MOF) composition for sorbing and/or desorbing CO 2 , and a gas flow outlet. Embodiments of the present disclosure describe an anesthetic system comprising one or more regeneratable cartridges for sorbing and/or desorbing CO 2 , wherein each of the one or more regeneratable cartridge includes a metal-organic framework composition, wherein at least one of the regeneratable cartridges includes a SIFSIX-3-Cu MOF. Embodiments of the present disclosure describe an alkaline fuel cell comprising a catalyst layer including a SIFSIX-3-Cu MOF composition for sorbing and/or desorbing CO 2 .

Claims (21)

1. A metal-organic framework (MOF) composition, the MOF composition comprising:

a SIFSIX-n-M MOF including a metal (M) and a ligand, wherein n is at least 2;

wherein the metal is selected from the group consisting of Co, Mn, Mo, Cr, Fe, Ca, Ba, Cs, Pb, Pt, Pd, Ru, Rh, and Cd.

2. The MOF composition of claim 1 , wherein the ligand is a nitrogen-containing heterocyclic ligand.

3. The MOF composition of claim 1 , wherein the ligand is selected from the group consisting of pyridine, 4,4′-Bipyridin, pyrazine, pyrimidine, pyridazine, triazine, thiazole, oxazole, pyrrole, imidazole, pyrazole, triazole, oxadiazole, thiadiazole, quinoline, benzoxazole, benzimidazole, 1,4-Diazabicyclo[2.2.2]octane (DABCO), 1,2-bis(4-pyridyl)acetylene (dpa), and tautomers thereof.

4. The MOF composition of claim 1 , wherein the ligand is pyridine, 4,4′-Bipyridin, pyrimidine, pyridazine, triazine, thiazole, oxazole, pyrrole, imidazole, pyrazole, triazole, oxadiazole, thiadiazole, quinoline, benzoxazole, benzimidazole, 1,4-Diazabicyclo[2.2.2]octane (DABCO), or tautomers thereof.

5. The MOF composition of claim 1 , wherein the ligand is dipryidilacetylene.

6. The MOF composition of claim 1 , wherein the ligand is pyrazine.

7. The MOF composition of claim 1 , wherein the MOF includes square grids pillared by (SiF 6 ) 2− anions.

8. The MOF composition of claim 7 , wherein the square grids include the metal and the ligand.

9. The MOF composition of claim 7 , wherein the square grids include pyrazine/M(II), wherein M(II) is Co, Mn, Mo, Cr, Fe, Ca, Ba, Cs, Pb, Pt, Pd, Ru, Rh, or Cd.

10. An anesthetic system comprising: one or more regeneratable cartridges for sorbing and/or desorbing CO 2 from a fluid, wherein the one or more regeneratable cartridges includes the MOF composition of claim 1 .

11. The anesthetic system of claim 10 , wherein the CO 2 in the fluid has a partial pressure of 125 mbar or less.

12. The anesthetic system of claim 10 , wherein the fluid includes exhaled air.

13. An alkaline fuel cell comprising: a catalyst layer for sorbing and/or desorbing CO 2 from a fluid, wherein the catalyst layer includes the MOF composition of claim 1 .

14. The alkaline fuel cell of claim 13 , wherein the CO 2 in the fluid has a partial pressure of 125 mbar or less.

15. The alkaline fuel cell of claim 13 , wherein the fluid is air.

16. A metal-organic framework (MOF) composition, the MOF composition comprising:

a SIFSIX-n-M MOF including a metal (M) and a ligand, wherein n is at least 2, M is Cu, and wherein the ligand is pyridine, pyrimidine, pyridazine, triazine, thiazole, oxazole, pyrrole, imidazole, pyrazole, triazole, oxadiazole, thiadiazole, quinoline, benzoxazole, benzimidazole, 1,4-Diazabicyclo [2.2.2]octane (DABCO), or tautomers thereof.

17. A metal-organic framework (MOF) composition, the MOF composition comprising:

a SIFSIX-n-M MOF including a metal (M) and a ligand, wherein n is at least 2, M is Zn, and wherein the ligand is pyridine, 4,4′-Bipyridin, pyrimidine, pyridazine, triazine, thiazole, oxazole, pyrrole, imidazole, pyrazole, triazole, oxadiazole, thiadiazole, quinoline, benzoxazole, benzimidazole, 1,4-Diazabicyclo [2.2.2]octane (DABCO), or tautomers thereof.

Continuity (5)
Division 16280481 · Feb 20, 2019
Continuation 15507411
Provisional Application 62044927 · Sep 2, 2014
Provisional Application 62044928 · Sep 2, 2014
Related Publication 20200398209A1 · Dec 24, 2020